Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPT193 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT05399368Phase 2Terminated
- Sponsor
- RAPT Therapeutics
- Start
- Jun 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of zelnecirnon in atopic dermatitis (AD) (4 arms), sponsored by RAPT Therapeutics. Primary endpoint: Clinical Efficacy at 16 weeks. Started Jun 2022; status: terminated.
02
Drugs
zelnecirnon
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05399368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05399368.